BMS Reports the US FDA’s Acceptance of Opdivo’s sBLA for Priority Review to Treat Muscle Invasive Urothelial Carcinoma Published: Apr 30, 2021 | Tags: BMS, US, FDA, Opdivo, sBLA, Priority […]readmore
Tags : Vifor Pharma
Shots: The companies have completed the enrolment in P-II AKI-002-15 study evaluating the safety and efficacy of ANG-3777 (2.0 mg/kg, IV) vs PBO over 4 days in patients with CSA-AKI […]readmore
Shots: The companies partnered to form JV focusing on the marketing, market access, and medical affairs activities for the IV iron portfolio. Vifor Pharma will own 55% while the Fresenius […]readmore
Shots: Evotec to apply its drug discovery & development capabilities plus will utilize Vifor Pharma’s platform for creating pipeline of nephrology program and with the completion of clinical trials evaluating […]readmore
Shots: Vifor and Janssen collaborated to jointly commercialize Invokana (canagliflozin) to treat DKD and to reduce the risk of hospitalization for heart failure in patients with T2D and DKD in […]readmore